The toxic effects of aluminum have been recognized in recent years as the cause of a number of important disorders, particularly in patients on long-term hemodialysis for chronic renal failure. The predominant clinical features include dementia [1], myopathy [2], and bone disease [3]. Initial studies of aluminum-induced bone disease demonstrated that fractures were significantly more common in patients exposed to high dialysate aluminum concentration and phosphate binders [3]. Whereas most of the early investigations concentrated on linking the aluminum level of the dialysate to induction of bone disease, recently excessive ingestation of antacids has been found to be a more important source of aluminum toxicity. Severe osteomalacic changes were found in patients treated with aluminum-containing antacids [4, 5]. We describe the radiographic manifestations of aluminum-induced bone disease in two hypencalcemic patients. Both received longterm, high-dose antacid therapy. After the diagnosis of aluminum-induced bone disease was made by iliac crest bone biopsy, each patient improved dramatically on defenoxamine therapy with rapid fracture healing.
[1]
H. Spencer,et al.
Antacid-induced calcium loss.
,
1983,
Archives of internal medicine.
[2]
H. Spencer,et al.
Effect of small doses of aluminum-containing antacids on calcium and phosphorus metabolism.
,
1982,
The American journal of clinical nutrition.
[3]
D. Lockwood,et al.
Osteomalacia and weakness from excessive antacid ingestion.
,
1980,
JAMA.
[4]
D. Citrin,et al.
Atlas of technetium bone scans
,
1977
.
[5]
W. Bloom,et al.
Osteomalacia with Pseudofractures Caused by the Ingestion of Aluminum Hydroxide
,
1960
.